Magic Power Coffee reveals a recall
This article was originally published in The Tan Sheet
Executive Summary
The distributors of Magic Power Coffee do not have a trick up their sleeve to make their product disappear from the market, but must rely on a recall. INZ Distributors Inc./Magic Power Coffee Inc. June 28 voluntarily recalled the dietary supplement in which FDA found hydroxythiohomosildenafil, an unapproved drug that is an analogue to sildenafil, the active ingredient in Pfizer's erectile dysfunction drug Viagra (1"The Tan Sheet" June. 28, 2010). The Brooklyn, N.Y., firm said no illnesses linked to the product have been reported. The recall covers production dates through May 8, 2010
You may also be interested in...
FDA brews up Magic Power Coffee warning
The distributor of a coffee product found to contain an analogue of the erectile dysfunction drug sildenafil receives an official FDA warning letter Aug. 23, following a consumer advisory and voluntary recall in June (1"The Tan Sheet" July 5, 2010, In Brief). INZ Distributors of Brooklyn, N.Y., sells an unapproved, misbranded new drug, the agency's New York District office says. Magic Power Coffee is an adulterated food, due to the presence of an ingredient not generally recognized as safe, and improperly labeled as a dietary supplement given its representation as a conventional food/beverage, FDA says. INZ faces product seizures and possible injunction if it fails to correct the violations within 15 days, according to the letter
FDA Lifts Curtain On The Secret Behind Magic Power Coffee
FDA's consumer advisory against a coffee product that contains an active drug ingredient for erectile dysfunction reflects the agency's growing capability to keep up with noncompliant firms that add drug substances to so-called dietary supplements
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: